PASG
Passage BIO, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.55
+4.41%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.46
From 52W high−82.12%
Volume24345.00
Market cap$11.42M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$3.46
From 52W high
−82.12%
Volume
24345.00
Market cap
$11.42M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
P/E (TTM)
—
RSI (14)
42.9
MomentumView details →
1D Return
+4.41%
YTD Return
−70.22%
SummaryUpdated Jun 1, 2026
Passage Bio, Inc. (NASDAQ:PASG) is a clinical-stage genetic medicines company founded in 2017 and headquartered in Philadelphia, Pennsylvania. The company went public in February 2020 and focuses on developing transformative gene therapies for rare central nervous system diseases. Passage Bio leverages adeno-associated virus (AAV) gene therapy technology to deliver functional genes directly to the brain and peripheral tissues, targeting devastating neurological conditions that currently have no effective treatments.
Similar companies
Latest newsMore news →
Passage BIO, Inc. amended and restated its merger agreement with Remix Therapeutics, Inc., changing the structure to a two-step merger and permitting the concurrent financing to be funded through pre-funded warrants.62d agoPassage Bio and Remix Therapeutics announced a merger agreement, with the combined company to operate as Remix Therapeutics and advance Remix's pipeline of novel small molecule therapies.133d ago